Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | POLR1A | O95602 | 1/20 | 0.30 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL862165 | 0.85 | GRM2 (0.31) | IDO1TDO2IDO2GRM2MAP4K1 | |
| SCHEMBL832789 | 0.84 | GABRG2 (0.36) | GABRG2GABRB3GABRA5IDO1TDO2 | |
| SCHEMBL10255776 | 0.72 | KMT2A (0.34) | GABRG2GABRB3GABRA5IDO1TDO2 | |
| SCHEMBL13394518 | 0.71 | IDO1 (0.33) | IDO1TDO2IDO2POLR1A | |
| SCHEMBL833262 | 0.70 | IDO1 (0.34) | IDO1TDO2IDO2POLR1A | |
| SCHEMBL832643 | 0.70 | PDPK1 (0.46) | GABRG2GABRB3GABRA5 | |
| SCHEMBL13210054 | 0.70 | MAP2K4 (0.36) | GABRG2GABRB3GABRA5 | |
| SCHEMBL10299255 | 0.69 | L3MBTL1 (0.45) | — | |
| SCHEMBL14920239 | 0.68 | BACE1 (0.41) | GABRG2GABRB3GABRA5 | |
| SCHEMBL2779797 | 0.68 | NR1H2 (0.39) | GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | GABRG2 3809/4885GABRB3 2957/4885GABRA5 2096/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | GABRG2 4196/4885GABRB3 3107/4885GABRA5 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.